Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

BACKGROUND: PCSK9 inhibitor therapy has been approved by the FDA as an adjunct to diet-maximal tolerated cholesterol lowering drug therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) with suboptimal LDL cholesterol (LDL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lipids Health Dis
Main Authors: Shah, Parth, Glueck, Charles J., Jetty, Vybhav, Goldenberg, Naila, Rothschild, Matan, Riaz, Rashid, Duhon, Gregory, Wang, Ping
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991071/
https://ncbi.nlm.nih.gov/pubmed/27538393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12944-016-0302-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados